Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Nicholson

Showing results (231-240 of 357) with videos related to

Pageof 36
Sort By:
Endocrine-Related Cancer|August 23, 2005
Development of strategies for the use of anti-growth factor treatmentsH E Jones, J M W Gee, K M Taylor, et al.
Lancet (London, England)|December 12, 1981
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapyF C Campbell, R W Blamey, C W Elston, et al.
Cancer Research|January 10, 2002
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastKai C Chan, W Fiona Knox, Julia M Gee, et al.
The Journal of Pathology|July 9, 1999
p21(WAF1) expression and endocrine response in breast cancerR A McClelland, J M Gee, L O'Sullivan, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1992
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survivalA P Locker, K Birrell, J A Bell, et al.
Hormone Research|January 1, 1989
Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancerR I Nicholson, K J Walker, R F Walker, et al.
Endocrine-Related Cancer|August 23, 2005
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancerR I Nicholson, I R Hutcheson, S E Hiscox, et al.
Breast Cancer Research and Treatment|May 22, 2008
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cellsS Hiscox, N J Jordan, C Smith, et al.
The Journal of Pathology|November 1, 1995
A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancersJ M Gee, A Douglas-Jones, P Hepburn, et al.
Cancer Research|August 1, 1986
Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter studyG Leclercq, H Bojar, J Goussard, et al.
Pageof 36

Showing results (231-240 of 357) with videos related to

Sort By:
Pageof 36
Endocrine-Related Cancer|August 23, 2005
Development of strategies for the use of anti-growth factor treatmentsH E Jones, J M W Gee, K M Taylor, et al.
Lancet (London, England)|December 12, 1981
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapyF C Campbell, R W Blamey, C W Elston, et al.
Cancer Research|January 10, 2002
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastKai C Chan, W Fiona Knox, Julia M Gee, et al.
The Journal of Pathology|July 9, 1999
p21(WAF1) expression and endocrine response in breast cancerR A McClelland, J M Gee, L O'Sullivan, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1992
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survivalA P Locker, K Birrell, J A Bell, et al.
Hormone Research|January 1, 1989
Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancerR I Nicholson, K J Walker, R F Walker, et al.
Endocrine-Related Cancer|August 23, 2005
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancerR I Nicholson, I R Hutcheson, S E Hiscox, et al.
Breast Cancer Research and Treatment|May 22, 2008
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cellsS Hiscox, N J Jordan, C Smith, et al.
The Journal of Pathology|November 1, 1995
A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancersJ M Gee, A Douglas-Jones, P Hepburn, et al.
Cancer Research|August 1, 1986
Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter studyG Leclercq, H Bojar, J Goussard, et al.
Pageof 36